David A. Siegel Mereo Biopharma Group PLC Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
Shares
3 transactions
Others Institutions Holding MREO
# of Institutions
88Shares Held
85.6MCall Options Held
182KPut Options Held
249K-
Rubric Capital Management LP New York, NY13.6MShares$48.8 Million1.52% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA9.33MShares$33.6 Million0.06% of portfolio
-
Mangrove Partners New York, NY8.75MShares$31.5 Million3.09% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD8.14MShares$29.3 Million0.7% of portfolio
-
683 Capital Management, LLC New York, NY5.75MShares$20.7 Million1.62% of portfolio
About Mereo Biopharma Group plc
- Ticker MREO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,986,000
- Market Cap $450M
- Description
- Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...